Article Text

PDF

Clinical sciences poster session 3: HIV
P3-S3.09 New drugs targeting toxicities have highest hope of impacting patient prognosis
  1. M Smit1,
  2. C Smit2,
  3. I Cremin1,
  4. T Hallett1,
  5. F de Wolf2,
  6. G Garnett1
  1. 1Imperial College, London, UK
  2. 2HIV Monitoring Foundation, Amsterdam, Netherlands

Abstract

Background As more HIV drugs enter the market there is a need to evaluate the effect of various antiretroviral therapies (ART) on patient outcomes. We aim to quantify the impact of different first- and second-line ART strategies on patient outcome including TMC278, an investigative non-nucleoside reverse-transcriptase inhibitors, thought to have low toxicity rates.

Methods A deterministic model was developed representing a cohort of 100 000 HIV-infected individuals. The model was parameterised using data from Athena; a cohort encompassing all patients infected with HIV-1 followed longitudinally since 1996 at 25 HIV treatment centres in the Netherlands. Clinical, biological and immunological data for HIV-infected patients are collected upon entry and at each follow-up visit. The model allows comparison of different ART strategies and of the impact of adverse outcomes: (I) toxicity; (II) general failure and (III) resistance on time on ART and life-years saved per person treated.

Results One of the main reasons for switching treatment is toxicity; therefore, new drugs aimed at reducing toxicity will be valuable. The model shows that if TMC278 can reduce incidence of toxicity leading to discontinuation of first-line ART from 74 to 49 per 1000 patients per year (34%) compared with current treatment then this would equate to one additional life-year saved per patient (Abstract P3-S3.09 figure 1). In comparison, a reduction in general failure from 38 to 25 incidences per 1000 patients per year (34%) adds 6 months and a reduction in resistance from 13 to 1 incidence per 1000 patients per year (92%) adds only 5 months (Abstract P3-S3.09 figure 1). For second-line, reducing incidence of toxicity from 143 to 53 per 1000 patients per year (63%) will add one life-year to per patient. This compares favourably with empirical estimates of toxicity for TMC278 in clinical trials (70% reduction in toxicity leading to discontinuation of first-line ART compared with efavirenz). The model also shows that by reducing rates of toxicity for first-line ART, consequently improving patient prognosis, patients on average spend more time on first-line ART before switching. Decreasing toxicity by 34% equates to an additional 18 months on first-line ART and a 61% decrease in toxicity equates to about five additional years on first-line ART.

Abstract P3-S3.09 Figure 1

Increase in life-expectancy per person treated with reduced annual incidence of adverse outcomes per 1000 patients for first-line ART. The red markers indicate empirical data; the blue markers indicate simulated estimates.

Conclusions New drugs which target a reduction in toxicities have the highest impact on patient prognosis, and such drugs are within reach of current candidate products.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.